Valuation : IXICO plc

Market Cap 16.35M 22.12M 19.05M 18.04M 30.68M 2.11B 30.84M 214M 82.4M 1.07B 83.06M 81.23M 3.4B P/E 2026 *
-5.36x
P/E 2027 * -5.77x
Enterprise Value 6.15M 8.32M 7.17M 6.79M 11.54M 795M 11.6M 80.63M 31.01M 404M 31.25M 30.57M 1.28B EV / Sales 2026 *
0.77x
EV / Sales 2027 * 1.14x
Free-Float
89.22%
Yield 2026 *
-
Yield 2027 * -
3 years 0.07
Extreme 0.07
0.15
5 years 0
Extreme 0.003
1.09
10 years 0
Extreme 0.003
1.47
Manager TitleAgeSince
Chief Executive Officer 53 2024-08-18
Director of Finance/CFO 50 2019-08-20
Chief Tech/Sci/R&D Officer - 2025-05-31
Director TitleAgeSince
Chairman 51 -
Director/Board Member 50 2019-08-20
Director/Board Member 60 2022-01-20
Change 5-day change 1-year change 3-year change Capi.($)
-53.33%-.--% - - 22.12M
-0.71%-6.35%-2.99%+9.59% 45.48B
+0.21%-2.98%+337.74%+519.55% 43.68B
+1.74%-2.24%+39.82%+20.76% 43.09B
+1.38%-3.28%+6.84%+67.62% 39.4B
-1.44%-5.26%+8.97%+39.76% 31.91B
+0.87%-2.60% - - 17.31B
+0.75%-0.64%+19.75%+110.17% 16.4B
-0.31%-2.78%+10.78%+31.02% 14.24B
+1.93%-3.55%+82.00%+41.17% 13.28B
Average -4.89%-3.57%+62.86%+104.96% 29.42B
Weighted average by Cap. +0.41%-3.67%+74.57%+124.26%

Financials

2026 *2027 *
Net sales 8M 10.82M 9.32M 8.83M 15.01M 1.03B 15.08M 105M 40.31M 526M 40.63M 39.74M 1.66B 9M 12.17M 10.49M 9.93M 16.88M 1.16B 16.97M 118M 45.35M 592M 45.71M 44.71M 1.87B
Net income -2.14M -2.9M -2.5M -2.36M -4.02M -277M -4.04M -28.08M -10.8M -141M -10.88M -10.65M -445M -2.8M -3.79M -3.26M -3.09M -5.25M -362M -5.28M -36.7M -14.11M -184M -14.23M -13.91M -582M
Net Debt -10.2M -13.79M -11.88M -11.25M -19.14M -1.32B -19.23M -134M -51.4M -670M -51.8M -50.67M -2.12B -6.1M -8.25M -7.11M -6.73M -11.44M -788M -11.5M -79.93M -30.74M -401M -30.98M -30.3M -1.27B
Logo IXICO plc
IXICO plc is engaged in neuroscience imaging and biomarker analytics, using its artificial intelligence (AI)-driven platform to help advance drug development in neurological disorders. The Company is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Alzheimer's disease, Parkinson's disease and Huntington's disease. It advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include imaging biomarkers, trial management, data analytics, consultancy and post-marketing surveillance. Its TrialTracker platform provides a standardized, compliant and efficient workflow for capturing visual read results of MRI, SPECT, PET and CT scans, supporting single, over-read and double adjudicated read paradigms.
Employees
79
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0750GBP
Average target price
0.2600GBP
Spread / Average Target
+246.67%

Annual profits - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!